Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.77 -3.37%

-$0.34 today

Market cap
$186.36M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.97M

Average 0.48M

ARTV EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Artiva Biotherapeutics, Inc.NASDAQ: ARTV

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$22.85M, compared with -$19.68M a year earlier. Trailing-twelve-month EBITDA was -$84.44M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly EBITDA holds near -$22.85M or moves back toward the trailing-twelve-month quarterly average of -$21.11M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$22.85M-13.6% QoQ
Last fiscal yearDec 2025
-$81.27M-45.0% YoY
LTMMar 2026
-$84.44M-35.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.1%——
1 year-45.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

EBITDA history

USD · from the income statement

Latest · FY2025
(81.27M) USD
Year-over-year change
-45.0%

EBITDA vs competitors

How ARTV compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -35.4% is the 7th highest of 9, against a peer median of +16.2%.
ARTV Competitors
EBITDA for ARTV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DTILPrecision BioSciences, Inc.LTM Mar 2026-$40.42M USD-143.9%—89.7%
IFRXInflaRx N.V.LTM Mar 2026-€42.36M EUR+1.6%—144435.8%
STTKShattuck Labs, Inc.LTM Mar 2026-$46.23M USD+30.8%—4623.1%
CNTBConnect Biopharma Holdings LimitedFY2025-$54.58M USD-270.2%—85279.7%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$84.44M USD-35.4%——
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$86.7M USD+32.0%——
STROSutro Biopharma, Inc.LTM Mar 2026-$106.12M USD+42.0%—106.5%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026-$106.88M USD-21.2%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$130.98M USD+37.9%——
Peer median (excluding ARTV) —+16.2%—4623.1%

Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2M4.93M33.49M251K0
Cost of Revenue00002.6M
Gross Profit2M4.93M33.49M251K(2.6M)
Gross Margin100.0%100.0%100.0%100.0%—
Research & Development42.41M43.98M50.25M50.33M69.54M
Selling, General & Admin12.86M20.78M13.91M17.21M20.27M
Operating Expenses55.27M64.76M64.16M67.53M88.01M
Depreciation & Amortization248K1.16M2.27M2.43M2.6M
EBITDA(71.58M)(57.18M)(25.36M)(56.06M)(81.27M)
EBITDA Margin-3575.3%-1159.5%-75.7%-22335.5%—
Operating Income(53.27M)(59.83M)(30.67M)(67.28M)(90.61M)
Operating Margin-2660.9%-1213.3%-91.6%-26805.6%—
Interest Income01.29M2.54M5.35M5.96M
Interest Expense00000
Other Income / Expenses(18.55M)1.49M3.05M8.79M6.75M
Income Before Tax(71.83M)(58.34M)(27.62M)(58.49M)(83.87M)
Pre-Tax Margin-3587.7%-1183.0%-82.5%-23304.0%—
Income Tax Expense053K72K00
Net Income(71.83M)(58.39M)(27.7M)(58.49M)(83.87M)
Net Margin-3587.7%-1184.1%-82.7%-23304.0%—
EPS (Basic)(4.08)(3.32)(1.19)(5.20)(3.43)
EPS (Diluted)(4.08)(3.32)(1.19)(5.20)(3.43)
Weighted Avg Shares17.58M17.58M23.28M24.36M24.44M
Weighted Avg Shares (Diluted)17.58M17.58M23.28M24.36M24.44M

Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Intrinsic Alpha fair value

Locked

Current Price

$3.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.